Rheumatoid arthritis can affect your liver, though the connection is often indirect. The biggest liver risks for people with RA come from the medications used to manage the disease, but RA itself also drives systemic inflammation that can stress the liver, and it shares genetic overlap with several autoimmune liver conditions. About 1 in 3 RA patients has fatty liver disease, and long-term use of common RA drugs like methotrexate carries a measurable risk of liver fibrosis.
How RA Itself Affects the Liver
Rheumatoid arthritis is a systemic inflammatory disease, meaning its effects extend well beyond the joints. The chronic inflammation circulating throughout your body can reach the liver, triggering changes in liver tissue even without any primary liver disease. Liver biopsies from RA patients commonly show increased activity of immune cells in the liver, inflammatory cells accumulating in the liver’s portal tracts, fatty deposits, and cell swelling. About 25% of RA patients show mild fibrosis (scarring) around the liver’s portal areas, and roughly 13% develop scarring near the center of liver lobules.
These changes are often silent. You may have no symptoms at all, or your routine blood work might show mildly elevated liver enzymes that seem puzzling. The inflammation driving your joint disease is the same inflammation nudging your liver toward these tissue changes.
Felty Syndrome and Liver Enlargement
Felty syndrome is a complication that develops in a small subset of people with long-standing, severe RA. It involves an enlarged spleen and dangerously low white blood cell counts. What many people don’t realize is that 68% of Felty syndrome patients also develop an enlarged liver (hepatomegaly). This makes it one of the most common extra-articular features of the syndrome, second only to rheumatoid nodules. If you have severe, long-duration RA and notice fullness or discomfort in your upper right abdomen, liver involvement is worth investigating.
Autoimmune Liver Diseases and RA
RA shares immune system pathways with several autoimmune liver conditions, and having one raises your odds of developing the other. Primary biliary cholangitis (PBC), a condition where the immune system slowly destroys the bile ducts inside the liver, is the most common autoimmune liver disease seen alongside RA. PBC occurs in roughly 4% to 6% of RA patients, and some studies report rates as high as 10%. Looking at it from the other direction, RA shows up in anywhere from 2% to 13% of people who already have PBC.
Autoimmune hepatitis, where your immune system attacks liver cells directly, also overlaps with RA. Among people diagnosed with autoimmune hepatitis, between 1.6% and 5.4% also have RA. Overall, RA can be identified in about 5% of people living with various autoimmune liver diseases, including PBC, autoimmune hepatitis, and primary sclerosing cholangitis.
These aren’t side effects of medication. They’re separate autoimmune conditions that tend to cluster together because of shared immune dysfunction. If your liver enzymes are persistently elevated and your medications have been ruled out as the cause, your doctor may consider screening for these conditions.
Methotrexate and Liver Damage
Methotrexate is the most widely prescribed first-line medication for RA, and its potential to harm the liver is well documented. Long-term use is associated with gradual, often symptom-free liver scarring that can progress over years. Roughly 30% of patients on long-term methotrexate develop mild-to-moderate tissue changes visible on biopsy, including fatty infiltration and low-grade inflammation. More concerning, 2% to 20% develop some degree of liver fibrosis depending on the study and dosing pattern.
In one study following 27 RA patients over several years, none had fibrosis before starting methotrexate, but fibrosis rates climbed to 8% at two years, 16% at three years, and 40% at four years. Progression correlated with how long people stayed on the drug, their age, and whether they drank alcohol. A large meta-analysis combining data from both RA and psoriasis patients found advanced fibrosis in about 5% of those on long-term, low-dose methotrexate.
Actual cirrhosis from methotrexate in RA patients is rare. A survey of US rheumatologists identified just 24 verifiable cases of cirrhosis attributable to methotrexate, with an estimated rate of 0.1% after five years of use. But “rare” isn’t “zero,” and the risk rises with higher cumulative doses, older age, and alcohol consumption. Daily dosing schedules (rather than the standard once-weekly dosing used for RA) carry substantially higher cirrhosis risk.
Other RA Medications That Stress the Liver
Methotrexate gets the most attention, but other RA drugs also affect liver enzymes. Leflunomide, another common disease-modifying drug, causes mild enzyme elevations in up to 15% of patients. These are usually transient and resolve on their own. More significant elevations (above three times the normal upper limit) occur in 1% to 4% of patients. Clinically apparent liver injury from leflunomide is rare, estimated at roughly 1 in 1,000 to 1 in 5,000 people, but when it happens it can be severe.
Biologic therapies that block a key inflammation molecule called TNF are also associated with liver enzyme changes. In one study of 363 patients on TNF inhibitors, 23.7% developed some degree of enzyme elevation. Among the specific drugs, adalimumab trended toward a slightly higher risk while infliximab appeared to carry a lower risk, though most elevations were mild.
Newer targeted drugs called JAK inhibitors, such as tofacitinib, show enzyme elevations in 28% to 34% of patients in clinical trials, compared to about 10% on placebo. Significant elevations above three times normal occurred in 1% to 2% of patients. These were typically mild and temporary, but they underscore the need for regular monitoring with any RA therapy.
Fatty Liver Disease in RA Patients
A systematic review and meta-analysis found that 35.3% of RA patients have nonalcoholic fatty liver disease (NAFLD), meaning roughly 1 in 3 people with RA have excess fat accumulation in their liver. Interestingly, this rate appears comparable to the general population’s overall NAFLD prevalence, so RA may not independently increase your risk. However, the combination of chronic inflammation, metabolic changes from reduced physical activity, corticosteroid use, and the liver stress from RA medications can make fatty liver more consequential when it does occur.
If you already have fatty liver disease and start methotrexate, the American College of Rheumatology recommends more frequent liver monitoring, every 4 to 8 weeks, even if your liver enzymes and function tests are normal at baseline. Fatty liver makes the organ more vulnerable to additional insults from medication.
What Liver Monitoring Looks Like
If you’re on any disease-modifying RA drug, regular blood tests checking liver enzymes are a standard part of your care. These are simple blood draws, typically done every few months once you’re on a stable dose, and more frequently when starting a new medication or adjusting doses. The goal is to catch enzyme elevations early, before any meaningful liver damage occurs, so your treatment plan can be adjusted.
Most enzyme elevations in RA patients are mild, temporary, and resolve either on their own or with a dose adjustment. Progression to serious liver disease is uncommon with proper monitoring. The key factors that increase your risk of more significant liver problems include heavy alcohol use, older age, higher cumulative drug doses, obesity, and having a pre-existing liver condition like fatty liver disease or viral hepatitis. Minimizing alcohol intake, maintaining a healthy weight, and keeping up with your scheduled blood work are the most practical steps you can take to protect your liver while managing RA.